Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.

With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily used to treat Type 2 diabetes and obesity. Recent research has expanded their potential applications ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription is associated with reductions in risk-adjusted ...

A new study reports that GLP-1 medications may provide benefits to cognitive and behavioral health, including lowered addiction risk. Scientists also confirmed that the use of these medications ...